Rheumatology International

, Volume 32, Issue 11, pp 3619–3624

Appraising osteoporosis care gaps


    • Department of RheumatologyGeisinger Medical Center
  • Jana L. Antohe
    • Department of RheumatologyGeisinger Medical Center
  • Elaine Sunderlin
    • Department of Internal MedicineUniversity of North Carolina
  • Thomas M. Harrington
    • Department of RheumatologyGeisinger Medical Center
Original Article

DOI: 10.1007/s00296-011-2203-5

Cite this article as:
Olenginski, T.P., Antohe, J.L., Sunderlin, E. et al. Rheumatol Int (2012) 32: 3619. doi:10.1007/s00296-011-2203-5


To evaluate physician response to dual-energy X-ray absorptiometry (DXA) report within the Geisinger Medical Center’s Mobile DXA Program and treatment adherence at 1 year. Between 10/01/2004 and 3/30/2005, 1381 DXA scans were performed in our Mobile DXA Program. Within this cohort, we identified 366 high-risk, drug-naive patients and report the percentage of patients placed on prescription drug therapy within 90 days of DXA result. Additionally, we identified 191 patients with Z-score of −1.0 or worse and report whether laboratory tests were ordered within 90 days of DXA results in this group. Finally, we determined treatment adherence at 1 year. 269 patients (74%) were offered prescription therapy within 3 months of DXA results. Of those, 210 (57%) were still adherent to drug therapy at 1 year. The main reason for discontinuation of treatment was an adverse drug side effect. Additionally, in 50% cases, physicians ordered 1 or more laboratory tests to evaluate low Z-score. Within our Mobile DXA Program, 74% of high-risk, drug-naïve patients were treated. Interestingly, in 50% cases, when a low Z-score was reported, our physicians ordered 1 or more laboratory tests. Treatment adherence was 57% at 1 year.


Osteoporosis DXA Osteoporosis care gap Fracture risk Treatment adherence Bisphosphonates Glucocorticoid induced osteoporosis program

Copyright information

© Springer-Verlag 2011